Compounds > phosphoribofuranosylbarbituric acid
Page last updated: 2024-11-08

phosphoribofuranosylbarbituric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID161647
CHEMBL ID383923
SCHEMBL ID2130675
MeSH IDM0091393

Synonyms (20)

Synonym
6-hydroxyuridine 5'-(dihydrogen phosphate)
1LOR
6-hydroxy-ump
1DQX
1EIX
DB02890
6-hydroxyuridine-5''-phosphate
bdbm50199178
1-beta-d-ribofuranosyl(3h)pyrimidine-2,4,6-trione 5''-monophosphate
3,4-dihydroxy-5-(6-oxido-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)tetrahydrofuran-2-yl)methyl phosphate
prfb acid
CHEMBL383923 ,
29741-00-2
SCHEMBL2130675
phosphoribofuranosylbarbituric acid
barbituric acid ribonucleoside 5'-phosphate
5'-uridylic acid, 6-hydroxy-
DTXSID50183892
6-hydroxyuridine 5'-phosphate
PD059766
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, OROTIDINE 5'-PHOSPHATE DECARBOXYLASESaccharomyces cerevisiae (brewer's yeast)Ki0.00000.00000.00000.0000AID977610
Chain B, OROTIDINE 5'-PHOSPHATE DECARBOXYLASESaccharomyces cerevisiae (brewer's yeast)Ki0.00000.00000.00000.0000AID977610
Chain A, OROTIDINE 5'-MONOPHOSPHATE DECARBOXYLASEEscherichia coliKi0.00000.00000.00000.0000AID977610
Chain B, OROTIDINE 5'-MONOPHOSPHATE DECARBOXYLASEEscherichia coliKi0.00000.00000.00000.0000AID977610
Chain A, orotidine 5'-monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.00000.000050.1185200.0000AID977610
Chain B, orotidine 5'-monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.00000.000050.1185200.0000AID977610
Chain A, orotidine 5'-monophosphate decarboxylaseArchaeaKi0.00000.000050.1185200.0000AID977610
Chain A, orotidine monophosphate decarboxylaseMethanothermobacter thermautotrophicusKi0.00000.000050.1185200.0000AID977610
Chain A, orotidine monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.00000.000050.1185200.0000AID977610
Chain B, orotidine monophosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi0.00000.000050.1185200.0000AID977610
Orotidine 5'-phosphate decarboxylaseSaccharomyces cerevisiae S288CKi0.00000.00000.03200.0640AID488232; AID488233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 2Homo sapiens (human)EC50 (µMol)100.00000.00560.682810.0000AID272716
P2Y purinoceptor 4Homo sapiens (human)EC50 (µMol)100.00000.02301.362310.0000AID272719
P2Y purinoceptor 6Homo sapiens (human)EC50 (µMol)100.00000.01302.393020.0000AID272722
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
intracellular monoatomic ion homeostasisP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of mucus secretionP2Y purinoceptor 2Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 2Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 4Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 4Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
phagocytosisP2Y purinoceptor 6Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
activation of phospholipase C activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of smooth muscle cell migrationP2Y purinoceptor 6Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic processP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeP2Y purinoceptor 6Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 6Homo sapiens (human)
cellular response to purine-containing compoundP2Y purinoceptor 6Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationP2Y purinoceptor 6Homo sapiens (human)
cellular response to pyrimidine ribonucleotideP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
protein bindingP2Y purinoceptor 2Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 2Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 2Homo sapiens (human)
protein bindingP2Y purinoceptor 4Homo sapiens (human)
ATP bindingP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor activityP2Y purinoceptor 6Homo sapiens (human)
protein bindingP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UDP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 4Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 4Homo sapiens (human)
presynaptic active zone membraneP2Y purinoceptor 4Homo sapiens (human)
glutamatergic synapseP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 6Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 6Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID393526Antitumor activity against human MCF7 cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393521Antitumor activity against human LOX cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID272724Agonist activity at human P2Y6 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA at 100 uM2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID393536Antitumor activity against human PC3 cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393518Antitumor activity against human OCI-My 2 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID272722Agonist activity at human P2Y6 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID393527Antitumor activity against human MDA468 cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393534Antitumor activity against human T47D cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393538Antitumor activity against human SNB19 cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393520Antitumor activity against human MCF7 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393530Cytotoxicity against human CCD-967 cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID272719Agonist activity at human P2Y4 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID393532Antitumor activity against human Hs 578T cells up to 50 uM after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393515Antitumor activity against human OCI-AML1 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID488233Inhibition of Saccharomyces cerevisia uridine 5'-monophosphate synthase2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.
AID393519Antitumor activity against human SKW3 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID272721Agonist activity at human P2Y4 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA at 100 uM2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID393524Antitumor activity against human COLO205 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393522Antitumor activity against human MDA468 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393523Antitumor activity against human OVCAR4 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID272718Agonist activity at human P2Y2 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA at 100 uM2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID393517Antitumor activity against human OCI-LY7 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID488232Inhibition of Saccharomyces cerevisia uridine 5'-monophosphate synthase after overnight incubation at room temperature by VP-ITC microcalorimetry2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.
AID393516Antitumor activity against human OCI-AML2 cells after 3 days by WST1 assay2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID272716Agonist activity at human P2Y2 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002The Journal of biological chemistry, Aug-02, Volume: 277, Issue:31
Crystal structures of inhibitor complexes reveal an alternate binding mode in orotidine-5'-monophosphate decarboxylase.
AID1811Experimentally measured binding affinity data derived from PDB2002The Journal of biological chemistry, Aug-02, Volume: 277, Issue:31
Crystal structures of inhibitor complexes reveal an alternate binding mode in orotidine-5'-monophosphate decarboxylase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Biochemistry, Apr-18, Volume: 39, Issue:15
Structural basis for the catalytic mechanism of a proficient enzyme: orotidine 5'-monophosphate decarboxylase.
AID1811Experimentally measured binding affinity data derived from PDB2000Biochemistry, Apr-18, Volume: 39, Issue:15
Structural basis for the catalytic mechanism of a proficient enzyme: orotidine 5'-monophosphate decarboxylase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Proceedings of the National Academy of Sciences of the United States of America, Feb-29, Volume: 97, Issue:5
Anatomy of a proficient enzyme: the structure of orotidine 5'-monophosphate decarboxylase in the presence and absence of a potential transition state analog.
AID1811Experimentally measured binding affinity data derived from PDB2000Proceedings of the National Academy of Sciences of the United States of America, Feb-29, Volume: 97, Issue:5
Anatomy of a proficient enzyme: the structure of orotidine 5'-monophosphate decarboxylase in the presence and absence of a potential transition state analog.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.59 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uridine monophosphate
Uridine Monophosphate: 5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. uridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.		2.0110pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uridine diphosphate
Uridine Diphosphate: A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.		2.0310pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
uridine triphosphate
Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.		2.0310pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
5-fluorouridine
[no description available]		2.0510organofluorine compound;
uridines		mutagen
xanthosine 5'-triphosphate
xanthosine 5'-phosphate : xanthosine phosphate compounds having phosphate groups at position 5'.. 5'-xanthylic acid : A purine ribonucleoside 5'-monophosphate having xanthine as the nucleobase.		2.0110purine ribonucleoside 5'-monophosphate;
xanthosine 5'-phosphate		Escherichia coli metabolite;
metabolite;
mouse metabolite
5-fluorouridine 5'-phosphate
5-fluorouridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having 5-fluorouracil as the pyrimidine component.		2.0510organofluorine compound;
pyrimidine ribonucleoside 5'-monophosphate		drug metabolite
6-azauridine-5'-monophosphate
6-azauridine-5'-monophosphate: RN given refers to parent cpd. 6-azauridine 5'-monophosphate : A N-glycosyl-1,2,4-triazine that is the 6-aza analogue of uridine 5'-monophosphate.		2.4320N-glycosyl-1,2,4-triazine;
nucleoside monophosphate analogue		antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
5-bromouridine triphosphate
5-bromouridine 5'-triphosphate : A pyrimidine ribonucleoside 5'-triphosphate having 5-bromouracil as the pyrimidine component.		2.0310organobromine compound;
pyrimidine ribonucleoside 5'-triphosphate
ConditionIndicatedRelationship StrengthStudiesTrials